saj
2月前
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceThrough its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
GLOBENEWSWIRE 4:42 AM ET 4/20/2026
Symbol Last Price Change
PBM 7.6up 0 (0%)
QUOTES AS OF 04:00:00 PM ET 04/17/2026
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd.(PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand.
Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence BioMed has spent the past year advancing a purpose-built platform designed to support ibogaine-based programs across development and potential commercialization.
Through its investment in and collaboration with PsyLabs, the Company has established an integrated supply and GMP-compliant manufacturing platform spanning sourcing at origin, extraction, purification, and pharmaceutical production. This platform is designed to enable consistent, high-quality output while supporting the requirements of clinical and regulated environments.
Operating at the natural source of ibogaine in Africa, PsyLabs has secured direct access to raw materials and in-region processing capabilities, supporting traceability, supply continuity, and ethical sourcing practices aligned with long-term sustainability and community engagement.
The Company is positioned to support partners across the value chain – from early-stage research through to clinical development and potential commercialization – helping to facilitate program advancement and supply in a market where access to pharmaceutical-grade ibogaine remains limited.
Globally, pharmaceutical-grade ibogaine supply remains limited, fragmented, and largely non-integrated, making access to standardized, GMP-compliant material a critical constraint on clinical progress. Psyence BioMed’s vertically integrated platform, supported by its GMP inventory, is designed to help address this gap.
A Commercial Moat: GMP Doses Ready for Research
As a key operational milestone, the Company confirms it currently holds standardized, stabilized, and GMP-compliant ibogaine doses in inventory. This supply is designed to support ongoing and future research initiatives, providing immediate access to pharmaceutical-grade material and helping to reduce delays associated with supply constraints.
In addition to high-purity ibogaine, the Company supports the development of total alkaloid extracts, enabling flexibility across therapeutic approaches and supporting continued research into both single-compound and full-spectrum modalities.
“Recent regulatory signals underscore what we have believed for some time – that ibogaine warrants rigorous, structured evaluation,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “Over the past year, we have been building toward this moment – establishing supply, manufacturing capability, and inventory so that we are ready to support clinical research as regulatory pathways evolve.”
“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” Aufrichtig added. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”
By aligning source-level access, GMP manufacturing capabilities, and available inventory, Psyence BioMed is positioned to support the growing ecosystem of researchers, developers, and institutions working to advance ibogaine-based therapies.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.(PBM)
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
iHub News
4月前
Psyence Biomedical Shares Rise Following Equity Investment AgreementFebruary 23, 2026 11:16 AM
IH Market News
Psyence Biomedical Ltd. (NASDAQ:PBM) shares climbed 4.4% in premarket trading Monday after the company announced plans to acquire an equity stake in Psyence Labs Ltd. through a share-for-share transaction.The deal comes after Psyence Labs exercised a previously disclosed put option. Under the agreement, Psyence Biomedical will acquire 2,900 Psyence Labs shares, representing a total value of $5 million based on an assessed fair market price of $1,724 per share.In return, Psyence Biomedical will issue 1,146,159 of its common shares to Psyence Labs, calculated using a 30-day volume-weighted average price of $4.36 per share. The transaction does not involve any cash payment.Once completed, Psyence Labs is expected to hold approximately 49.98% of Psyence Biomedical’s outstanding common stock, based on the 1,147,148 shares outstanding prior to the issuance.Closing of the transaction is anticipated on or around February 25, 2026, subject to standard closing requirements. These include confirmation of Psyence Labs’ valuation documentation and verification that no material adverse developments have occurred in its business.Psyence Biomedical said the investment enhances strategic alignment between the two companies and reinforces its long-term supply framework as clinical development and commercialization efforts progress. The firms already maintain licensing and supply agreements covering pharmaceutical-grade psychedelic compounds.The transaction was reviewed and approved by a special committee of independent directors, which evaluated both the commercial rationale and an independent third-party valuation of Psyence Labs. Certain Psyence Biomedical executives currently provide consulting services to Psyence Labs and together hold less than 13% of its outstanding equity.Psyence Biomedical stock price
Original: Psyence Biomedical Shares Rise Following Equity Investment Agreement
makinezmoney
4月前
$PBM: Just had its split......... so should run
Halted now at $9.60
Seen these kinda things before.
GO $PBM
*******************************************************************************************
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
By Psyence Biomedical Ltd. | January 28, 2026, 6:30 PM
Share
PBM
+95.07%
Psyence Biomedical Ltd
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026, however, following further internal consideration, the Company yesterday announced that it had elected to delay the effectiveness of the reverse stock split to a later date.
At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a ratio of up to 1-for-50, with the exact timing and consolidation ratio to be determined in the Board’s sole discretion. Following this approval, the Company's Board of Directors initially authorized a 1-for-7.97 consolidation ratio which was implemented Monday, May 5, 2025. On December 4, 2025, the board approved a second share consolidation at a ratio of 1-for-6.25.
The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on February 2, 2026. Following the consolidation, the Company's common shares will continue to trade under the symbol "PBM" on the Nasdaq Capital Market, with a new CUSIP number 74449F407.
At the effective time of the consolidation, every 6.25 issued and outstanding shares of the Company will automatically be combined into one issued and outstanding common share. The number of shares and the exercise price of the Company's outstanding warrants and other equity instruments will also be adjusted proportionately in accordance with their respective terms. As of January 21, 2026, the Company had 6,388,604 common shares issued and outstanding. As a result of the consolidation, the Company will have 1,022,177 common shares issued and outstanding.
No fractional shares will be issued in connection with the consolidation. Any fractional share resulting from the consolidation will be rounded down to the nearest whole share if the fraction is less than one-half of a share and rounded up to the nearest whole share if the fraction is at least one-half of a share. The consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company, except for minor adjustments resulting from the treatment of fractional shares. The share consolidation occurs at the registered shareholder level. Shareholders who hold their common shares through brokers, banks, or other nominees (i.e., in 'street name') are considered beneficial holders and may experience a delay in the reflection of the consolidation in their accounts, depending on the procedures of their broker, bank, or nominee.
Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the consolidation. Shareholders holding their shares in book-entry form or through brokerage accounts are not required to take any action. Beneficial holders are encouraged to contact their broker, bank, or custodian with any questions regarding the effect of the share consolidation.
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the timing and implementation of the share consolidation, the expected timing for the Company’s common shares to begin trading on a post-consolidated basis, the Company’s ability to maintain compliance with Nasdaq’s continued listing standards, the anticipated effects of the share consolidation (including on the market price of the Company’s common shares), the issuance of a new CUSIP number, and the expected timing of adjustments to outstanding warrants and other equity instruments and the reflection of the share consolidation in brokerage and other accounts. These statements are based on current assumptions and expectations, including that the share consolidation will become effective as anticipated, and that the Company will continue to meet Nasdaq’s ongoing listing standards. These assumptions may prove incorrect. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among others: (i) delays or challenges in completing the share consolidation; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price following the consolidation; (iv) changes in the regulatory, competitive, and economic landscape; (v) risks associated with the Company’s development plans and clinical trials; and (vi) risks related to the Company’s corporate authorizations for the share consolidation, including the possibility of claims or proceedings challenging the validity, interpretation or sufficiency of the shareholder resolutions authorizing the share consolidation. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Mentioned In This Article
PBM
+95.07%
Psyence Biomedical Ltd
tw0122
6月前
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity ScienceDecember 09 2025 - 7:00AM
http://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Fpsyence-biomedical-PBM%2Fstock-news%2F97402780%2Fpsyence-biomed-ceo-letter-highlights-clinical-prog
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026.In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science.“We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the exciting field of Longevity and ended the year debt free with over USD $9 million in cash reserves.”Clinical Progress and Phase IIb Trial MomentumPsyence BioMed advanced its Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care. Multiple patients were dosed across several Australian clinical sites, supported by a partnership with Southern Star Research, one of Australia's leading clinical research organisations.Advancing Nature-Derived Manufacturing and Supply Chain LeadershipThe Company strengthened its vertical integration through a multi-million-dollar follow-on investment in PsyLabs, securing GMP compliant nature-derived psilocybin and ibogaine supply for current and future programs. Psyence BioMed also announced a breakthrough in high purity ibogaine production, reinforcing its manufacturing advantage.Regulatory Tailwinds in AustraliaAufrichtig noted the importance of the Australian Therapeutic Goods Administration’s (TGA) public consultation on psilocybin-assisted therapy for existential distress in patients with life-limiting illness – a development closely aligned with the Company’s clinical trial. If approved, the amendment would enable supervised access through the Authorised Prescriber framework and expand the eligible prescriber group to include palliative-care specialists.A Unique Position in Longevity Science“Psyence BioMed is currently the only publicly listed psychedelics company investing meaningfully in longevity science,” said Aufrichtig. “Our focus is on the emotional, neurobiological, and existential dimensions of aging, and we believe psychedelic-assisted therapy will play a central role in improving healthspan – not just lifespan.”2026 OutlookThe Company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, pursue additional longevity-focused indications, and evaluate strategic partnership opportunities throughout 2026.The full CEO Letter is available on the Company’s website at: www.psyencebiomed.com.About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The company is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental
tw0122
6月前
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity ScienceDecember 09 2025 - 7:00AM
https://twitter.com/sharehttp://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Fpsyence-biomedical-PBM%2Fstock-news%2F97402780%2Fpsyence-biomed-ceo-letter-highlights-clinical-prog
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026.In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science.“We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the exciting field of Longevity and ended the year debt free with over USD $9 million in cash reserves.”Clinical Progress and Phase IIb Trial MomentumPsyence BioMed advanced its Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care. Multiple patients were dosed across several Australian clinical sites, supported by a partnership with Southern Star Research, one of Australia's leading clinical research organisations.Advancing Nature-Derived Manufacturing and Supply Chain LeadershipThe Company strengthened its vertical integration through a multi-million-dollar follow-on investment in PsyLabs, securing GMP compliant nature-derived psilocybin and ibogaine supply for current and future programs. Psyence BioMed also announced a breakthrough in high purity ibogaine production, reinforcing its manufacturing advantage.Regulatory Tailwinds in AustraliaAufrichtig noted the importance of the Australian Therapeutic Goods Administration’s (TGA) public consultation on psilocybin-assisted therapy for existential distress in patients with life-limiting illness – a development closely aligned with the Company’s clinical trial. If approved, the amendment would enable supervised access through the Authorised Prescriber framework and expand the eligible prescriber group to include palliative-care specialists.A Unique Position in Longevity Science“Psyence BioMed is currently the only publicly listed psychedelics company investing meaningfully in longevity science,” said Aufrichtig. “Our focus is on the emotional, neurobiological, and existential dimensions of aging, and we believe psychedelic-assisted therapy will play a central role in improving healthspan – not just lifespan.”2026 OutlookThe Company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, pursue additional longevity-focused indications, and evaluate strategic partnership opportunities throughout 2026.The full CEO Letter is available on the Company’s website at: www.psyencebiomed.com.About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The company is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedel
tw0122
7月前
a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs.This collaboration with PsyLabs is an important step in securing a long-term supply of high-quality active pharmaceutical ingredients. PsyLabs’ ibogaine is fully GMP-compliant, ensuring it meets the rigorous standards required for clinical development. The first 50 kg has already been received and is now being processed into ibogaine HCL – the purified, pharmaceutical-grade form of ibogaine designed for precise dosing in clinical research – and into Total Alkaloid Extracts, which preserve the broader spectrum of iboga alkaloids found in the natural plant. Together, these products will be supplied to the legal research and treatment industries, supporting both standardized clinical trials and research into full-spectrum therapeutic approaches.Investing in a sustainable approach ensures that ibogaine and related alkaloids derived from and are ethically sourced and pharmaceutical grade. By prioritizing quality, sustainability, and respect for the cultural traditions connected to these plants – including fair benefit-sharing with source communities – the Company is building a vertically integrated supply chain that meets the highest standards while supporting the long-term viability of this essential resource.“A reliable, ethically sourced supply of ibogaine is critical to our development pipeline,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “This achievement not only strengthens our ability to advance our ibogaine-based clinical programs but also positions Psyence BioMed as a global leader in the emerging ibogaine sector. As international interest in ibogaine continues to accelerate, securing a sustainable and culturally respectful supply chain gives us a meaningful competitive advantage and reinforces our commitment to scientific rigor, responsible innovation, and the preservation of traditional knowledge.”"From soil to science, we will continue to ensure our ibogaine is not only the purest on the market, but the most ethically sourced," said Tony Budden, CEO of PsyLabs. "We’re building a new standard for what ethical psychedelic production can look like – where traditional knowledge holders are partners, not just suppliers."Today’s announcement advances Psyence BioMed – together with PsyLabs – toward a leading role in shaping the future of ibogaine development for substance use disorders and other urgent mental health needs.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Zardiw
2月前
ErnieBilco
2月前
glenn1919
4月前
81vette
10月前
MomsSpaghetti
10月前
Golden Cross
1年前
メールアドレスで登録
